# Hanquyou

Type: Product

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/hanquyou
Canonical HTML page: https://getfinancebrief.com/entity/hanquyou

## Timeline

- **2026-03-24**: Annual Results — Official release of 2025 financial performance data to global markets.
- **2025-11-10**: Global Partnership — Strategic agreement signed for the distribution of biosimilars in emerging markets.
- **2025-08-20**: CAR-T Milestone — Fosun Kite announces expanded indications for Yi Kai Da CAR-T therapy.
- **2025-03-15**: Regional Launch — Serplulimab receives regulatory approval in additional Southeast Asian markets.

## Recent coverage (1 stories)

### Fosun Pharma 2025 Results Highlight Innovation Pivot and Global Expansion
2026-03-24 17:03:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Fosun Pharma reported robust 2025 financial results, driven by a record contribution from innovative drugs and successful expansion into Southeast Asian markets. The company's strategic focus on high-barrier biologics and R&D has solidified its transition from a generic-focused manufacturer to a global innovation leader.
Full story: https://getfinancebrief.com/story/fosun-pharma-2025-annual-results-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.